Medizinische Universität Graz - Research portal
Navigation/Search
- Researchers
- Institutions
- Projects
- Publications
- Partners
- Sponsors
- Equipment
- Knowhow
- Fields of Research
"Faces" of the day:
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Nicholls, SJ; Pavo, I; Bhatt, DL; Buse, JB; Del, Prato, S; Kahn, SE; Lincoff, AM; McGuire, DK; Miller, D; Nauck, MA; Nishiyama, H; Nissen, SE; Sattar, N; Weerakkody, G; Wiese, RJ; Zinman, B; Zoungas, S; Basile, J; Davies, MJ; Giorgino, F; Kellerer, M; Ji, L; Varkonyi, T; Menon, V; Broder, JC; Herschtal, A; D'Alessio, D, , SURPASS-CVOT, Investigators.
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
N Engl J Med. 2025; 393(24):2409-2420
Doi: 10.1056/NEJMoa2505928
PubMed
FullText
FullText_MUG
- Authors Med Uni Graz:
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight. The effects on cardiovascular outcomes are uncertain. METHODS: We conducted an active-comparator-controlled, double-blind, noninferiority trial in which patients with type 2 diabetes and atherosclerotic cardiovascular disease were randomly assigned in a 1:1 ratio to receive a weekly subcutaneous injection of tirzepatide (up to 15 mg) or dulaglutide (1.5 mg), an agent that has been shown to reduce the incidence of cardiovascular events. The primary end point was a composite of death from cardiovascular causes, myocardial infarction, or stroke and was tested for noninferiority of tirzepatide to dulaglutide with a margin of 1.05 for the upper limit of the 95.3% confidence interval for the hazard ratio. An upper limit of less than 1.00 was considered to indicate superiority of tirzepatide to dulaglutide. RESULTS: A total of 13,299 patients underwent randomization; 134 were subsequently excluded because they did not meet inclusion criteria. The modified intention-to-treat population thus included 6586 patients in the tirzepatide group and 6579 in the dulaglutide group. The mean (±SD) age of the patients was 64.1±8.8 years, 29.0% were women, the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 32.6±5.5, the mean glycated hemoglobin level was 8.4±0.9%, and the mean duration of diabetes was 14.7±8.8 years. A primary end-point event occurred in 801 patients (12.2%) in the tirzepatide group and 862 (13.1%) in the dulaglutide group (hazard ratio, 0.92; 95.3% confidence interval, 0.83 to 1.01; P = 0.003 for noninferiority; P = 0.09 for superiority). The incidence of adverse events appeared to be similar in the two groups, although more gastrointestinal adverse events were observed in the tirzepatide group. CONCLUSIONS: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to a composite of death from cardiovascular causes, myocardial infarction, or stroke. (Funded by Eli Lilly; SURPASS-CVOT ClinicalTrials.gov number, NCT04255433.).
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Female - administration & dosage
- Humans - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Blood Glucose - analysis
- Cardiovascular Diseases - complications, drug therapy, mortality, prevention & control
- Diabetes Mellitus, Type 2 - drug therapy, complications, mortality, blood
- Double-Blind Method - administration & dosage
- Glucagon-Like Peptides - administration & dosage, adverse effects, analogs & derivatives
- Glycated Hemoglobin - analysis
- Immunoglobulin Fc Fragments - administration & dosage, adverse effects
- Injections, Subcutaneous - administration & dosage
- Intention to Treat Analysis - administration & dosage
- Recombinant Fusion Proteins - administration & dosage, adverse effects
- Tirzepatide - administration & dosage, adverse effects
- Glucagon-Like Peptide-1 Receptor Agonists - administration & dosage, adverse effects
- Treatment Outcome - administration & dosage